

Brendah K Masisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2861685/publications.pdf>

Version: 2024-02-01

9
papers

235
citations

1307594

7
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

282
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of glutaminase in cancer. <i>Histopathology</i> , 2020, 76, 498-508.	2.9	101
2	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 535-544.	2.5	36
3	Glutamate dehydrogenase (GLUD1) expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 79-91.	2.5	32
4	Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1407.	4.1	24
5	The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 1-12.	2.5	12
6	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. <i>BMC Cancer</i> , 2020, 20, 425.	2.6	10
7	The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 3963.	3.7	8
8	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. <i>Cancers</i> , 2020, 12, 1549.	3.7	7
9	SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 317-331.	2.5	5